The successful use of inhaled morphine to relieve dyspnea in a patient with end-stage cystic fibrosis ... decline in pulmonary function. The only treatment for end-stage CF lung disease is ...
The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) has shown clinically meaningful responses in pretreated patients with extensive-stage ... pulmonary fibrosis in interstitial lung ...
Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.
The effort by the Center for Regenerative Medicine of Boston University, Boston Medical Center, and GSK aims to find new ...
The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...
TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...
Lung transplantation stands as a critical option for patients suffering from end-stage diseases such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and cystic fibrosis ...
Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation from new investors Sanofi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback